Michael Konstan, M.D.
Chairman, Department of Pediatrics
Director of Cystic Fibrosis Center
Rainbow Babies & Childrens
(216) 844 3884 Phone
(216) 844 1479 Fax
Michael W. Konstan, MD is the Chairman of the Department of Pediatrics of Case Western Reserve University (CWRU) School of Medicine at Rainbow Babies and Children’s Hospital in Cleveland Ohio. He received his B.A. and M.D. degrees from CWRU. After completing his internship and residency in pediatrics at The Children’s Hospital of Buffalo, he returned to CWRU and Rainbow for fellowship training in Pediatric Pulmonology. He is currently a professor of pediatrics at CWRU, where he also serves as the director of CWRU’s Cystic Fibrosis Translational Therapeutics Development Center and Research Development Program. Dr. Konstan is also the director of The LeRoy W. Matthews Cystic Fibrosis Center at Rainbow Babies and Children’s Hospital.
Dr. Konstan’s academic career has focused on developing new therapies for the lung disease of cystic fibrosis (CF), with a special interest in anti-inflammatory therapies and clinical trial design. His research has been supported by grants from the Cystic Fibrosis Foundation, National Institutes of Health, and the Food and Drug Administration. He has led numerous national and international clinical trials of potentially new therapies for CF, and is regarded as a national and international expert in this disease. Dr. Konstan has published extensively, serves on many advisory boards and committees related to advancing the treatment of CF, and continues to care for a devoted cadre of patients with CF.
Dr. Konstan has received several national awards for his accomplishments, including the Richard C. Talamo Distinguished Clinical Achievement Award from the Cystic Fibrosis Foundation, and the “All Stars Among Us” award for community service from Major League Baseball and People Magazine.
VanDevanter DR, Rasouliyan L, Murphy TM, Morgan WJ, Ren CL, Konstan MW, Wagener JS; Investigators, Coordinators of the Epidemiologic Study of Cystic Fibrosis.
"Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005."
Pediatr Pulmonol. 2008 Aug;43(8):739-44.
Nichols DP, Konstan MW, Chmiel JF.
"Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease"
Clin Rev Allergy Immunol. 2008 Jun 11.
Konstan MW, Schluchter MD, Xue W, Davis PB.
"Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis"
Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084-9.
Sagel SD, Chmiel JF, Konstan MW.
"Sputum biomarkers of inflammation in cystic fibrosis lung disease.
Proc Am Thorac Soc. 2007 Aug 1;4(4):406-17. Review.
Konstan MW, Morgan WJ, Butler SM, Pasta DJ, et al.
"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis"
J Pediatr. 2007 Aug;151(2):134-9, 139.e1. Epub 2007 Jun 22.
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, et al.
"Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis."
Pediatr Pulmonol. 2007 Jul;42(7):610-23.
Ren CL, Morgan JW, Konstan MW, Schechter MS, Wagener JS, Fisher KA.
"Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function."
Pediatr Pulmonol. 2007 Jun;42(6):513-8.
Chmiel JF, Konstan MW
"Inflammation and anti-inflammatory therapies for cystic fibrosis."
Clin Chest Med. 2007 Jun;28(2):331-46. Review.
Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.
"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety."
Pediatr Pulmonol. 2007 Apr;42(4):307-13.
Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, et al
"Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function."
Pediatrics. 2007 Mar;119(3):e531-7.
Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagal SD, Ramsey BW
"Association between pulmonary function and sputum biomarkers in cystic fibrosis."
Am J Respir Crit Care Med. 2007 Apr 15;175(8):822-8. Epub 2007 Jan 18.
Borowitz D, Goss CH, Limauro S, Konstan MW, Blake K, Casey S, Quittner AL, Murray FT
"Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis."
J Pediatr. 2006 Nov;149(5):658-662.
McMullen AH, Pasta DJ, Frederick PD, Konstan MW, Morgan WJ, Schechter MS, Wagener JS.
"Classifying Severity of Cystic Fibrosis Lung Disease Using Longitudinal Pulmonary Function Data"
Am J Respir Crit Care Med. 2006 Jul 20
"Impact of pregnancy on women with cystic fibrosis"
Chest. 2006 Mar;129(3):706-11.
Blumer JL, Saiman L, Konstan MW, Melnick D.
"The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis"
Chest. 2005 Oct;128(4):2336-46
Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR; Gene Modifier Study Group.
"Genetic modifiers of lung disease in cystic fibrosis"
N Engl J Med. 2005 Oct 6;353(14):1443-53
Chmiel JF, Konstan MW
"Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent"
Treat Respir Med. 2005;4(4):255-73
Hart MA, Konstan MW, Darrah RJ, Schluchter MD, Goddard KA, Drumm ML
"Beta 2 adrenergic receptor polymorphisms in cystic fibrosis"
Pediatr Pulmonol. 2005 Jun;39(6):544-50, 2005
Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ
"Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution"
Hum Gene Ther. 15(12):1255-69, 2004
Davis PB, Schluchter MD, Konstan MW
"Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis"
Pediatr Pulmonol. 38(3):204-9, 2004
Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
"Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis"
J Pediatr. 2003 Jun;142(6):624-30
Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL
"Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects"
J Pharmacol Exp Ther. 306(3):1086-91, 2003
A.G. Ziady, P.B. Davis, and M.W. Konstan
"Novel non-viral gene transfer therapy for cystic fibrosis"
Expert Opinion on Biological Therapy. 3:449-458, 2003
Konstan MW, Davis PB
"Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis"
Adv Drug Deliv Rev. 54(11):1409-23, 2002
Schluchter MD, Konstan MW, Davis PB
"Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients"
Stat Med. 21(9):1271-87, 2002
Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester Kirchner H, Berger M
"Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice"
Am J Respir Crit Care Med. 2002 Apr 15;165(8):1176-81
Hilliard JB, Konstan MW, Davis PB
"Inflammatory mediators in CF patients"
Methods Mol Med. 70:409-31, 2002
van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, Erokwu B, Haxhiu MA, Ferkol TW
"Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice"
Am J Respir Crit Care Med. 161(1):271-9, 2000